Skip to main navigation Our Science AT-527 COVID-19 About Atea Investors Careers Contact INVESTOR RELATIONS News Releases Breadcrumb Investors News & Events News Releases Year 2021 November 22, 2021 Atea Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will participate in a virtual fireside chat at the 4th Annual READ MORE November 16, 2021 Atea Pharmaceuticals Provides Update on Strategic Collaboration with Roche Atea to lead global clinical trial development of AT-527 and regain ex-US commercial rights BOSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the strategic collaboration pursuant to which it READ MORE November 11, 2021 Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2021 Financial Results Phase 3 MORNINGSKY Protocol Amendment to Include New Primary Endpoint, Refined Patient Population and Increased Dose, with Plan to Accelerate Completion of Enrollment Infectious Virus Data Demonstrate AT-527’s Rapid and Potent Antiviral Activity Against COVID-19 in Phase 2 MOONSONG Overall Patient READ MORE November 4, 2021 Atea Pharmaceuticals to Host Third Quarter Financial Results Conference Call on November 11, 2021 BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, November 11, 2021 at 4:30 p.m. READ MORE October 19, 2021 Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting Topline Phase 2 MOONSONG trial results did not meet the primary endpoint in the overall population of patients with mild or moderate COVID-19, who were mostly low-risk with mild symptoms In high-risk patients with underlying health conditions, a reduction of viral load of approximately 0.5 log 10 READ MORE October 7, 2021 Atea Pharmaceuticals to Present Virology and Early Clinical Data at the ISIRV-WHO Virtual Conference 2021 BOSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will present analyses confirming data previously reported relating to the AT-527 COVID-19 clinical trial program at the ISIRV-WHO virtual READ MORE September 29, 2021 Atea Pharmaceuticals to Present at Guggenheim 2nd Annual Vaccines & Infectious Day Conference BOSTON, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea together with other members of the Atea management team, will READ MORE September 7, 2021 Atea Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference BOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea together with other members of the Atea management team, will READ MORE August 24, 2021 Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752’s Potent In Vitro and In Vivo Activity Against Dengue and Other Flaviviruses In vitro and in vivo data demonstrate favorable safety and potency against multiple dengue virus serotypes supporting ongoing clinical development of AT-752 Dengue is the fastest-spreading mosquito-borne viral disease with an estimated 400 million infections each year globally BOSTON, Aug. READ MORE August 12, 2021 Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Second Quarter 2021 Financial Results New Data in Healthy Volunteers Confirmed that AT-527’s Active Metabolite Achieved Target Antiviral Levels in Lungs, Key Site of COVID-19 Infection AT-527 Phase 2 Study Interim Results Showed Potent and Rapid Antiviral Activity in Hospitalized Patients; Study to Advance with Protocol Amendments READ MORE August 5, 2021 Atea Pharmaceuticals to Host Second Quarter Financial Results Conference Call on August 12, 2021 BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, August 12, 2021 at 4:30 p.m. READ MORE July 12, 2021 Atea Pharmaceuticals to Present at William Blair Biotech Focus Conference BOSTON, July 12, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced that Jean-Pierre Sommadossi, Ph.D., Founder, Chairman READ MORE Pagination CURRENT PAGE 1 PAGE 2 PAGE 3 NEXT PAGE NEXT › LAST PAGE LAST » Investor FAQs RSS Feeds Email Alerts Contact IR Atea is a clinical-stage biopharmaceutical company working to address unmet medical needs through novel antiviral treatment. Atea Pharmaceuticals, Inc. 125 Summer Street Boston, MA 02110 (857) 284-8891 Copyright © 2021 By Atea Pharmaceuticals, Inc. All Rights Reserved. Privacy Policy | Terms of Use